D'OXYVA

D'OXYVA is a biotech startup focused on improving lives by improving blood flow. The company's flagship product, D’OXYVA, is a deoxyhemoglobin vasodilator clinically validated to significantly enhance microcirculation. This innovative solution holds promise as an effective treatment option for a wide range of conditions. Founded in 2011 and headquartered in the United States, D'OXYVA operates in the biotechnology and health care sectors. As of now, there is no public information available regarding the last investment or the involved investors, making it an intriguing prospect for potential venture capital interest. The company's membership in the Forbes Los Angeles Business Council further underscores its growing reputation and potential for lucrative investment opportunities.